Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer

Clinical Breast Cancer - United States
doi 10.1016/j.clbc.2015.03.004
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Axillary Management of Stage II/III Breast Cancer in Patients Treated With Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative)

Journal of the American College of Surgeons
Surgery
2017English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Neoadjuvant Systemic Therapy in Breast Cancer

2012English

De-Escalated Therapy for HR+/HER2+ Breast Cancer Patients With Ki67 Response After 2 Weeks Letrozole: Results of the PerELISA Neoadjuvant Study

Annals of Oncology
MedicineOncologyHematology
2019English

A Randomized, Controlled Phase II Trial of Neoadjuvant Ado-Trastuzumab Emtansine, Lapatinib, and Nab-Paclitaxel Versus Trastuzumab, Pertuzumab, and Paclitaxel in HER2-positive Breast Cancer (TEAL Study)

Breast Cancer Research
Cancer ResearchOncology
2019English

18f-Fluorodeoxyglucose (FDG) PET/CT After Two Cycles of Neoadjuvant Therapy May Predict Response in HER2-negative, but Not in HER2-positive Breast Cancer

Oncotarget
Oncology
2015English

Predicting Successful Conservative Surgery After Neoadjuvant Chemotherapy in Hormone Receptor-Positive, HER2-Negative Breast Cancer

Journal of Breast Disease
2018English

Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction

Annals of Surgical Oncology
OncologySurgery
2019English

Cost-Effectiveness Analysis of Neoadjuvant Chemotherapy With Zoledronic Acid for HER2-Negative Breast Cancer in Japan: The JONIE1 Study

Health
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy